THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 123 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2022. The put-call ratio across all filers is 3.73 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $16,978,478 | -29.5% | 2,002,179 | -25.5% | 0.00% | – |
Q1 2024 | $24,092,101 | -38.6% | 2,685,853 | -23.0% | 0.00% | -100.0% |
Q4 2023 | $39,219,305 | +18.4% | 3,489,262 | -9.1% | 0.00% | 0.0% |
Q3 2023 | $33,133,409 | -24.1% | 3,839,329 | -9.0% | 0.00% | 0.0% |
Q2 2023 | $43,666,195 | -28.5% | 4,218,956 | -25.0% | 0.00% | -50.0% |
Q1 2023 | $61,049,978 | -2.1% | 5,626,726 | +1.2% | 0.00% | 0.0% |
Q4 2022 | $62,370,175 | +2.4% | 5,558,839 | -7.4% | 0.00% | 0.0% |
Q3 2022 | $60,903,000 | +2.7% | 6,006,133 | -8.2% | 0.00% | 0.0% |
Q2 2022 | $59,295,000 | -10.7% | 6,544,806 | -5.8% | 0.00% | 0.0% |
Q1 2022 | $66,421,000 | -4.6% | 6,947,947 | +10.3% | 0.00% | 0.0% |
Q4 2021 | $69,613,000 | +60.6% | 6,299,823 | +7.6% | 0.00% | +100.0% |
Q3 2021 | $43,339,000 | -43.5% | 5,856,555 | +10.9% | 0.00% | -50.0% |
Q2 2021 | $76,651,000 | -16.8% | 5,278,969 | +16.9% | 0.00% | 0.0% |
Q1 2021 | $92,153,000 | +11.4% | 4,515,115 | -3.0% | 0.00% | 0.0% |
Q4 2020 | $82,708,000 | +22.3% | 4,654,309 | +1.7% | 0.00% | 0.0% |
Q3 2020 | $67,640,000 | -31.4% | 4,574,878 | -2.6% | 0.00% | -33.3% |
Q2 2020 | $98,620,000 | -3.7% | 4,698,374 | +6.0% | 0.00% | -25.0% |
Q1 2020 | $102,448,000 | -1.2% | 4,433,056 | +10.7% | 0.00% | 0.0% |
Q4 2019 | $103,653,000 | +32.7% | 4,003,602 | -0.1% | 0.00% | +33.3% |
Q3 2019 | $78,097,000 | +21.6% | 4,009,033 | +1.9% | 0.00% | +50.0% |
Q2 2019 | $64,223,000 | -27.0% | 3,932,787 | +1.4% | 0.00% | -33.3% |
Q1 2019 | $87,920,000 | -13.7% | 3,878,225 | -2.6% | 0.00% | -40.0% |
Q4 2018 | $101,850,000 | -15.1% | 3,980,060 | +8.4% | 0.01% | 0.0% |
Q3 2018 | $119,965,000 | +49.2% | 3,672,030 | +3.6% | 0.01% | +66.7% |
Q2 2018 | $80,420,000 | -3.5% | 3,545,895 | +3.2% | 0.00% | -25.0% |
Q1 2018 | $83,347,000 | -12.1% | 3,436,946 | +1.1% | 0.00% | 0.0% |
Q4 2017 | $94,779,000 | -15.9% | 3,398,332 | +3.2% | 0.00% | -20.0% |
Q3 2017 | $112,754,000 | -11.5% | 3,293,055 | +3.0% | 0.01% | -16.7% |
Q2 2017 | $127,379,000 | +12.3% | 3,197,277 | +3.8% | 0.01% | 0.0% |
Q1 2017 | $113,417,000 | +20.4% | 3,080,296 | +4.2% | 0.01% | +20.0% |
Q4 2016 | $94,208,000 | -2.8% | 2,955,073 | +10.5% | 0.01% | -16.7% |
Q3 2016 | $96,946,000 | +74.3% | 2,675,147 | +9.1% | 0.01% | +100.0% |
Q2 2016 | $55,626,000 | +51.4% | 2,451,566 | +25.5% | 0.00% | +50.0% |
Q1 2016 | $36,740,000 | +24.7% | 1,954,216 | +8.7% | 0.00% | 0.0% |
Q4 2015 | $29,462,000 | +61.2% | 1,797,521 | +8.1% | 0.00% | +100.0% |
Q3 2015 | $18,281,000 | -12.4% | 1,663,407 | +3.7% | 0.00% | 0.0% |
Q2 2015 | $20,876,000 | -23.8% | 1,603,422 | +1.5% | 0.00% | -50.0% |
Q1 2015 | $27,411,000 | +23.6% | 1,579,867 | +6.3% | 0.00% | 0.0% |
Q4 2014 | $22,172,000 | -34.4% | 1,486,025 | +1.3% | 0.00% | -33.3% |
Q3 2014 | $33,820,000 | -22.6% | 1,467,246 | +7.1% | 0.00% | 0.0% |
Q2 2014 | $43,695,000 | – | 1,370,582 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Chescapmanager LLC | 1,157,718 | $17,117,000 | 2.77% |
Baupost Group | 8,735,168 | $129,149,000 | 1.40% |
Orbimed Advisors | 6,219,110 | $91,950,000 | 1.16% |
Rubric Capital Management LP | 550,747 | $8,143,000 | 0.76% |
Cormorant Asset Management, LP | 650,072 | $9,611,000 | 0.37% |
Rock Springs Capital Management LP | 824,018 | $12,183,000 | 0.31% |
Virtus ETF Advisers LLC | 23,148 | $342,000 | 0.18% |
Tekla Capital Management LLC | 298,470 | $4,413,000 | 0.16% |
PEREGRINE CAPITAL MANAGEMENT LLC | 412,594 | $6,100,000 | 0.16% |
NJ State Employees Deferred Compensation Plan | 38,142 | $564,000 | 0.10% |